CN102933707B - 稳定的α-半乳糖苷酶及其用途 - Google Patents

稳定的α-半乳糖苷酶及其用途 Download PDF

Info

Publication number
CN102933707B
CN102933707B CN201180022145.6A CN201180022145A CN102933707B CN 102933707 B CN102933707 B CN 102933707B CN 201180022145 A CN201180022145 A CN 201180022145A CN 102933707 B CN102933707 B CN 102933707B
Authority
CN
China
Prior art keywords
galactosidase
gal
alpha
activity
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180022145.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102933707A (zh
Inventor
阿维多尔·舒尔曼
伊利亚·鲁德费尔
泰里拉·本-摩西
塔利亚·谢赫提尔
亚尼瓦·阿聚莱
约瑟夫·沙尔提埃尔
塔利·基日涅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabogal Ltd
Original Assignee
Metabogal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Metabogal Ltd filed Critical Metabogal Ltd
Publication of CN102933707A publication Critical patent/CN102933707A/zh
Application granted granted Critical
Publication of CN102933707B publication Critical patent/CN102933707B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
CN201180022145.6A 2010-03-02 2011-03-02 稳定的α-半乳糖苷酶及其用途 Active CN102933707B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
US61/309,487 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
ILPCT/2010/000956 2010-11-17
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20
US61/434,503 2011-01-20
US61/434,499 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Publications (2)

Publication Number Publication Date
CN102933707A CN102933707A (zh) 2013-02-13
CN102933707B true CN102933707B (zh) 2015-09-30

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180022145.6A Active CN102933707B (zh) 2010-03-02 2011-03-02 稳定的α-半乳糖苷酶及其用途

Country Status (23)

Country Link
EP (3) EP2542675B1 (enExample)
JP (2) JP5758920B2 (enExample)
KR (1) KR101928403B1 (enExample)
CN (1) CN102933707B (enExample)
AU (1) AU2011222452B2 (enExample)
BR (2) BR112012022029B1 (enExample)
CA (1) CA2791461C (enExample)
DK (1) DK2865751T3 (enExample)
ES (2) ES2708843T3 (enExample)
FI (1) FIC20230032I1 (enExample)
FR (1) FR23C1041I2 (enExample)
HR (1) HRP20200428T1 (enExample)
HU (2) HUE030959T2 (enExample)
IL (2) IL221741A (enExample)
IN (1) IN2012MN02262A (enExample)
NL (1) NL301249I2 (enExample)
NO (1) NO2023041I1 (enExample)
NZ (2) NZ602317A (enExample)
PL (1) PL2865751T3 (enExample)
SG (2) SG183558A1 (enExample)
SI (1) SI2865751T1 (enExample)
WO (1) WO2011107990A1 (enExample)
ZA (1) ZA201206725B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
BR112012022029B1 (pt) * 2010-03-02 2022-10-11 Protalix Ltd Estrutura de proteina multimérica, seu uso e processo para preparação da estrutura de proteína multimérica
BR112013018516B1 (pt) * 2011-01-20 2023-11-07 Protalix Ltd Construto de expressão de ácido nucleico, método de produção de uma proteína alfa-galactosidase humana recombinante, proteína alfagalactosidase humana, composição farmacêutica, e, uso de uma proteína alfagalactosidase humana ou de uma composição
TWI642782B (zh) * 2013-10-23 2018-12-01 健臻公司 重組醣蛋白及其用途
US20170360900A1 (en) * 2014-12-22 2017-12-21 Codexis, Inc. Human alpha-galactosidase variants
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
PT3271453T (pt) 2015-03-17 2021-11-29 eleva GmbH Proteínas lisossomais glicosiladas, método de produção e usos
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2019008076A (es) * 2017-01-05 2019-08-29 Protalix Ltd Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.
WO2018225623A1 (ja) * 2017-06-07 2018-12-13 天野エンザイム株式会社 ラクターゼ原末及びラクターゼ製剤
US11427813B2 (en) 2018-12-20 2022-08-30 Codexis, Inc. Human alpha-galactosidase variants
JP2023516301A (ja) * 2020-02-28 2023-04-19 コデクシス， インコーポレイテッド ヒトアルファ－ガラクトシダーゼ変異体
KR20230110281A (ko) 2020-11-03 2023-07-21 프로탈릭스 리미티드 변형된 유리카제(uricase) 및 이의 용도
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) * 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006478A1 (en) * 1993-08-30 1995-03-09 Hawaii Biotechnology Group, Inc. RECOMBINANT COFFEE BEAN α-GALACTOSIDASE
CN1354796A (zh) * 1999-03-11 2002-06-19 核转移治疗公司 α－半乳糖苷酶缺陷的治疗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
EP1956085A2 (en) * 1997-09-05 2008-08-13 Altus Pharmaceuticals Inc. Carbohydrate crosslinked glycoprotein crystals
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
ATE303400T1 (de) * 1999-04-02 2005-09-15 Ajinomoto Kk Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
EP1523548B1 (en) 2002-05-15 2009-12-30 Agricultural Research Organization Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
WO2006108052A2 (en) * 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
ES2547726T3 (es) * 2005-11-18 2015-10-08 Tokyo Metropolitan Institute Of Medical Science Nueva enzima altamente funcional que tiene especificidad de sustrato modificada
US20100144008A1 (en) 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
AU2008290217B2 (en) 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
BR112012022029B1 (pt) * 2010-03-02 2022-10-11 Protalix Ltd Estrutura de proteina multimérica, seu uso e processo para preparação da estrutura de proteína multimérica

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006478A1 (en) * 1993-08-30 1995-03-09 Hawaii Biotechnology Group, Inc. RECOMBINANT COFFEE BEAN α-GALACTOSIDASE
CN1354796A (zh) * 1999-03-11 2002-06-19 核转移治疗公司 α－半乳糖苷酶缺陷的治疗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
蛋白质复合体及蛋白质相互作用研究新策略;王晓东等;《生物物理学报》;20090630;第25卷(第3期);157=167 *

Also Published As

Publication number Publication date
FR23C1041I2 (fr) 2024-08-02
EP2865751A1 (en) 2015-04-29
ES2606532T3 (es) 2017-03-24
RU2012141651A (ru) 2014-04-10
NL301249I2 (nl) 2023-12-14
AU2011222452A1 (en) 2012-09-27
SG183558A1 (en) 2012-10-30
NZ623294A (en) 2015-10-30
NZ602317A (en) 2014-04-30
FR23C1041I1 (enExample) 2023-12-29
BR112012022029A2 (pt) 2021-05-18
SI2865751T1 (sl) 2017-01-31
JP5871999B2 (ja) 2016-03-01
EP3088514B1 (en) 2018-11-28
NO2023041I1 (no) 2023-11-01
DK2865751T3 (en) 2017-01-09
RU2604795C2 (ru) 2016-12-10
KR20130056216A (ko) 2013-05-29
IL253249B (en) 2020-08-31
HRP20200428T1 (hr) 2020-06-12
IN2012MN02262A (enExample) 2015-06-12
KR101928403B1 (ko) 2018-12-14
EP2542675A1 (en) 2013-01-09
CN102933707A (zh) 2013-02-13
CA2791461C (en) 2019-10-22
NL301249I1 (enExample) 2023-11-08
BR112012022029B1 (pt) 2022-10-11
ZA201206725B (en) 2013-06-26
IL253249A (en) 2019-08-29
PL2865751T3 (pl) 2017-03-31
EP2865751B1 (en) 2016-09-14
FIC20230032I1 (fi) 2023-11-02
HUS2300038I1 (hu) 2023-11-28
EP3088514A1 (en) 2016-11-02
JP2013520986A (ja) 2013-06-10
CA2791461A1 (en) 2011-09-09
JP5758920B2 (ja) 2015-08-05
EP2542675B1 (en) 2014-12-17
JP2014237694A (ja) 2014-12-18
ES2708843T3 (es) 2019-04-11
WO2011107990A1 (en) 2011-09-09
HUE030959T2 (en) 2017-06-28
IL221741A (en) 2017-07-31
SG10201502609QA (en) 2015-05-28
HK1180720A1 (en) 2013-10-25
AU2011222452B2 (en) 2015-09-03
BR122014021216A2 (pt) 2021-06-01

Similar Documents

Publication Publication Date Title
CN102933707B (zh) 稳定的α-半乳糖苷酶及其用途
US12385026B2 (en) Stabilized alpha-galactosidase and uses thereof
EP2714752B1 (en) Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
JP6506250B2 (ja) 化学架橋剤
HK1180720B (en) Stabilized alpha-galactosidase and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant